Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Cancer Lett
; 473: 25-32, 2020 03 31.
Article
em En
| MEDLINE
| ID: mdl-31875523
ABSTRACT
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease. Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers. In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Hepatocelular
/
Terapia Viral Oncolítica
/
Ablação por Radiofrequência
/
Imunoterapia
/
Neoplasias Hepáticas
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article